Pacira Biosciences Inc
NASDAQ:PCRX
Intrinsic Value
Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. [ Read More ]
The intrinsic value of one PCRX stock under the Base Case scenario is 64.11 USD. Compared to the current market price of 25.5 USD, Pacira Biosciences Inc is Undervalued by 60%.
Valuation Backtest
Pacira Biosciences Inc
Run backtest to discover the historical profit from buying and selling PCRX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Pacira Biosciences Inc
Current Assets | 510m |
Cash & Short-Term Investments | 278.6m |
Receivables | 105.6m |
Other Current Assets | 125.9m |
Non-Current Assets | 1.1B |
Long-Term Investments | 38.5m |
PP&E | 234.9m |
Intangibles | 646.5m |
Other Non-Current Assets | 144.5m |
Current Liabilities | 97.4m |
Accounts Payable | 15.7m |
Accrued Liabilities | 73m |
Other Current Liabilities | 8.6m |
Non-Current Liabilities | 606.9m |
Long-Term Debt | 513.8m |
Other Non-Current Liabilities | 93.1m |
Earnings Waterfall
Pacira Biosciences Inc
Revenue
|
675m
USD
|
Cost of Revenue
|
-184.7m
USD
|
Gross Profit
|
490.3m
USD
|
Operating Expenses
|
-403m
USD
|
Operating Income
|
87.3m
USD
|
Other Expenses
|
-45.4m
USD
|
Net Income
|
42m
USD
|
Free Cash Flow Analysis
Pacira Biosciences Inc
PCRX Profitability Score
Profitability Due Diligence
Pacira Biosciences Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Pacira Biosciences Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
PCRX Solvency Score
Solvency Due Diligence
Pacira Biosciences Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Pacira Biosciences Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PCRX Price Targets Summary
Pacira Biosciences Inc
According to Wall Street analysts, the average 1-year price target for PCRX is 46.24 USD with a low forecast of 36.36 USD and a high forecast of 59.85 USD.
Ownership
PCRX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
PCRX Price
Pacira Biosciences Inc
Average Annual Return | 2.64% |
Standard Deviation of Annual Returns | 28.35% |
Max Drawdown | -69% |
Market Capitalization | 1.2B USD |
Shares Outstanding | 46 500 800 |
Percentage of Shares Shorted | 11.19% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Tampa, Florida and currently employs 697 full-time employees. The company went IPO on 2011-02-03. The firm is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain. Its iovera is a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Contact
IPO
Employees
Officers
The intrinsic value of one PCRX stock under the Base Case scenario is 64.11 USD.
Compared to the current market price of 25.5 USD, Pacira Biosciences Inc is Undervalued by 60%.